Please assess the completion status of the following clinical trial:

Trial Title: A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* chronic renal anemia;~* hemodialysis or peritoneal dialysis, with same mode of dialysis for \>=3 months before and throughout screening period;~* continuous maintenance epoetin alfa or beta therapy with the same dosing interval during the previous 2 months.~Exclusion Criteria:~* transfusion of red blood cells during previous 2 months;~* poorly controlled hypertension requiring interruption of epoetin alfa or beta treatment in past 6 months;~* significant acute or chronic bleeding such as overt gastrointestinal bleeding;~* hemolysis;~* folic acid and vitamin B12 deficiency.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RO0503821 (C.E.R.A.), 1x/4weeks (Type: EXPERIMENTAL): Eligible participants started RO0503821 (Continuous Erythropoietin Receptor Activator \[C.E.R.A\]) intravenously, at a dose of 120, 200 or 360 microgram (µg) every four weeks. The dose of C.E.R.A was based on the epoetin alfa or beta dose of\<8000, 8000-16000, or \>16000 international units (IU)/week, administered during the stability verification period (SVP) of 4 weeks. The SVP period was followed by dose titration period (DTP) of 16 weeks, efficacy evaluation period (EEP) of 8 weeks and long term safety period (LTSP) of 28 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).